Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AFFiRiS GmbH

http://www.affiris.com

Latest From AFFiRiS GmbH

Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed

Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.

Deal Watch Business Strategies

Three OTC COVID-19 Tests Win FDA Clearance After Template Updates

Access Bio’s CareStart COVID-19 Antigen test gives results within 10 minutes, Becton, Dickinson’s BD Veritor within 15 minutes and InBios International’s SCoV-2 Ag Detect within 20 minutes. All three hold emergency use authorizations.

Diagnostics Coronavirus COVID-19

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deals M & A

AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.

Deals Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • AFFiRiS AG
UsernamePublicRestriction

Register